NCT01793038

Brief Summary

Polycystic ovarian syndrome (PCOS) is a condition characterized by infertility, infrequent periods and amenorrhea or irregular bleeding plus anovulatory infertility. Clomid is the standard first drug of treatment for ovulation induction. Ovulation and conception will occur in approximately 75 and 30 percent of cases respectively. Cases not ovulating in response to doses of clomid up to 150 mg/day are known as clomid resistant PCOS.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2013

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 10, 2013

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 15, 2013

Completed
14 days until next milestone

Study Start

First participant enrolled

March 1, 2013

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2014

Completed
Last Updated

March 6, 2013

Status Verified

March 1, 2013

Enrollment Period

1.3 years

First QC Date

February 10, 2013

Last Update Submit

March 5, 2013

Conditions

Keywords

PCOSclomiphene citrate resistant PCOSAromatase inhibitors

Outcome Measures

Primary Outcomes (1)

  • ovulation rate

    percentage of ovulatory cycles per started and per completed cycles

    30 days

Secondary Outcomes (2)

  • endometrial thickness

    4 weeks

  • ongoing cycle pregnancy rate

    16 weeks

Study Arms (2)

CC-plus uFSH

ACTIVE COMPARATOR

clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12

Drug: clomiphene citrate-uFSH arm

Aromataze inhibitor plus uFSH

EXPERIMENTAL

Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12

Drug: Aromatase inhibitor (litrezole) plus uFSH arm

Interventions

literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12

Aromataze inhibitor plus uFSH

clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days

CC-plus uFSH

Eligibility Criteria

Age18 Years - 38 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • CC resistant PCOS
  • Infertile
  • Females
  • Age 18-38

You may not qualify if:

  • Hyperprolactinaemia
  • Cushing syndrome
  • Adult onset adrenal hyperplasia
  • Age \> 38
  • Other infertility factors in the couple than PCOS: male factor,tubal factor,edometriosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura Integrated fertility center

Al Mansurah, Dekahlia, Egypt

RECRUITING

Related Publications (2)

  • Abdellah MS. Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet. 2011 Jun;113(3):218-21. doi: 10.1016/j.ijgo.2010.11.026. Epub 2011 Apr 1.

    PMID: 21457973BACKGROUND
  • Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance. Curr Opin Obstet Gynecol. 2009 Dec;21(6):465-73. doi: 10.1097/GCO.0b013e328332d188.

    PMID: 19809318BACKGROUND

MeSH Terms

Conditions

Polycystic Ovary SyndromeInfertility

Interventions

Aromatase Inhibitors

Condition Hierarchy (Ancestors)

Ovarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Steroid Synthesis InhibitorsEnzyme InhibitorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesEstrogen AntagonistsHormone AntagonistsHormones, Hormone Substitutes, and Hormone AntagonistsPhysiological Effects of Drugs

Central Study Contacts

mohamad E GHanem, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

February 10, 2013

First Posted

February 15, 2013

Study Start

March 1, 2013

Primary Completion

June 1, 2014

Study Completion

September 1, 2014

Last Updated

March 6, 2013

Record last verified: 2013-03

Locations